These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32294856)

  • 1. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 2. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
    Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
    Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
    Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The diagnostic value of version 2.1 prostate imaging reporting and data system for prostate transitional zone lesions].
    Yang S; Zhang CY; Zhang YY; Tan SX; Wei CG; Shen XH; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3609-3613. PubMed ID: 33333685
    [No Abstract]   [Full Text] [Related]  

  • 12. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
    Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
    Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
    Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
    Eur Urol Focus; 2024 Jul; 10(4):634-640. PubMed ID: 37865591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Cui Y; Zhao J; Sun Y
    Urol Int; 2023; 107(10-12):959-964. PubMed ID: 38011845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
    Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
    Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
    Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
    World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
    Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
    Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.